Country: Canada
Language: English
Source: Health Canada
FINASTERIDE
JAMP PHARMA CORPORATION
G04CB01
FINASTERIDE
5MG
TABLET
FINASTERIDE 5MG
ORAL
30
Prescription
5 ALFA REDUCTASE INHIBITORS
Active ingredient group (AIG) number: 0124110001; AHFS:
APPROVED
2014-10-10
_JAMP-Finasteride_ _(finasteride) _ _ _ _ _ _ _ _Page 1 of 31_ PRODUCT MONOGRAPH PR JAMP-FINASTERIDE Finasteride Tablets, USP Film-coated Tablets 5 mg Type II 5α-reductase inhibitor JAMP PHARMA CORPORATION 1310 rue Nobel Boucherville, Quebec J4B 5H3, Canada DATE OF REVISION: April 5, 2023 SUBMISSION CONTROL NO.: 268915 _JAMP-Finasteride_ _(finasteride) _ _ _ _ _ _ _ _Page 2 of 31_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE .............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 4 WARNINGS AND PRECAUTIONS .................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 6 DRUG INTERACTIONS ..................................................................................................... 9 DOSAGE AND ADMINISTRATION .............................................................................. 10 OVERDOSAGE ................................................................................................................ 12 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 12 STORAGE AND STABILITY .......................................................................................... 13 SPECIAL HANDLING INSTRUCTIONS ....................................................................... 13 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................. 13 PART II: SCIENTIFIC INFORMATION ................................................................................ 14 PHARMACEUTICAL INFORMATION .......................................................................... Read the complete document